Photoisomerization of retinal protonated
Schiff base in microbial
and animal rhodopsins are strikingly ultrafast and highly specific.
Both protein environments provide conditions for fine-tuning the photochemistry
of their chromophores. Here, by combining time-resolved action absorption
spectroscopy and high-level electronic structure theory, we show that
similar control can be gained in a synthetically engineered retinal
chromophore. By locking the dimethylated retinal Schiff base at the
C11C12 double bond in its trans configuration (L-RSB), the excited-state decay is rendered from
a slow picosecond to an ultrafast subpicosecond regime in the gas
phase. Steric hindrance and pretwisting of L-RSB are found to be important
for a significant reduction in the excited-state energy barriers,
where isomerization of the locked chromophore proceeds along C9C10 rather than the preferred C11C12 isomerization path. Remarkably, the accelerated
excited-state dynamics also becomes steered. We show that L-RSB is
capable of unidirectional 360° rotation from all-trans to 9-cis and from 9-cis to all-trans in only two distinct steps induced by consecutive
absorption of two 600 nm photons. This opens a way for the rational
design of red-light-driven ultrafast molecular rotary motors based
on locked retinal chromophores.
Chemical modifications to the protonated Schiff-base retinal alter the photoabsorption as well as the excited-state dynamics significantly as revealed by gas-phase measurements.
Context. Extended red emission (ERE) denotes a broad unassigned feature extending from 540 to 800 nm observed in many regions of the interstellar medium (ISM), and is thought to originate from photoluminescence of cosmic dust. However, definitive assignment of specific carriers remains to be achieved. Aims. Our aim is to investigate the photoabsorption spectra of astrophysically relevant protonated oxygen-functionalized polycyclic aromatic hydrocarbons (OPAHs) to probe their ability to absorb photons in the near-ultraviolet (UV) and visible (vis) spectral region and to search for any low-lying electronic states that may account for the ERE. Methods. Gas-phase electronic action absorption spectra of the protonated OPAHs were recorded in the spectral range of 200−700 nm using the ELISA ion-storage ring. Additional time-dependent density functional theory (TD-DFT) calculations were performed to compute excited state transitions that complement the experimental spectra. Results. A set of five protonated (O)PAHs was considered, namely pentacene and the four oxygen-functionalized PAHs, pentacenequinone, pentacenetetrone, anthraquinone, and phenathrenequinone. All pentacene-related species show a main absorption band between 400 and 500 nm, while the smaller OPAHs, anthraquinone and phenanthrenequinone, generally absorb further to the blue compared to the pentacenes. Interestingly, pentacenequinone and phenanthrenequinone exhibit wide absorption plateaus towards the red side of their main absorption band(s), which places them among the potential candidates to contribute to ERE. Additional photodissociation mass spectra reveal the formation of smaller functionalized PAHs and small oxygen-bearing species. Conclusions. Our results demonstrate the ability of OPAHs to absorb in the UV/vis spectral region. Among the four studied OPAHs, two revealed very broad absorption characteristics at wavelengths up to 700 nm, which makes them suitable candidates to contribute to a part of the ERE spectrum. Moreover, these two OPAHs, pentacenequinone and phenanthrenequinone, could dissociate efficiently into oxygen-bearing molecules and smaller functionalized PAHs in photon-dominated regions (PDRs) of the ISM.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.